



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SUNDERRAJ et al

Atty. Ref.: LCM-687-139

Serial No. 10/556,900

TC/A.U.: 1614

Filed: November 15, 2005

Examiner: Unassigned

For: USE OF TRIPOLIDINE IN PROVIDING REFRESHEDNESS ON WAKING

* * * * *

January 30, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO/SB/08a.

Copies of U.S. Patent Publications are not required and are therefore not attached.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.


Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard D. Mitchard
Reg. No. 29,009

LCM:lff
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

687-139

10/556,900

APPLICANT

SUNDERRAJ et al

(Use several sheets if necessary)

FILING DATE

GROUP

November 15, 2005

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,906,943	06/2005	Kang			
	2004/0156885	08/2004	Zerbe et al			
	2002/0150544	10/2002	Zerbe et al			
	2002/0127190	09/2002	Zerbe et al			
	2001/0046511	11/2001	Zerbe et al			
	6,709,671	03/2004	Zerbe et al			
	6,592,887	07/2003	Zerbe et al			
	6,284,264	09/2001	Zerbe et al			
	6,177,096	01/2001	Zerbe et al			
	5,948,430	09/1999	Zerbe et al			
	2006/0039953	02/2006	Leung et al			
	2005/0031675	02/2005	Leung et al			
	2003/0211136	11/2003	Kulkarni et al			
	2003/0206942	11/2003	Kulkarni et al			
	2003/0206941	11/2003	Leung et al			
	2003/0054034	03/2003	Leung et al			
	2003/0008008	01/2003	Leung et al			
	2001/0022964	09/2001	Leung et al			
	7,025,983	04/2006	Leung et al			
	6,923,981	08/2005	Leung et al			
	6,596,298	07/2003	Leung et al			
	2005/0282869	12/2005	Raj			
	2004/0029927	02/2004	Sunderraj et al			
	2003/0134878	07/2003	Sunderraj			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 99/17753	04/1999	WO			X
WO 98/26780	06/1998	WO			X
WO 98/20862	05/1998	WO			X
WO 98/26763	06/1998	WO			X
WO 00/18365	04/2000	WO			
WO 03/047580	06/2003	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Monti, J.M., et al; "Histamine H ₁ Receptor Antagonists in the Treatment of Insomnia"; <i>CNS Drugs</i> ; 13(2), pp. 87-96 (2000).
Nicholson, A.N., et al; "Histaminergic Systems and Sleep"; <i>Neuropharmacol</i> ; 24(3); pp. 245-250 (1985).
Nicholson, A.N., et al; "Sedation and histamine H ₁ -receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene"; <i>Brit. J. Pharmacol</i> ; 104; pp. 270-276 (1991).
Nicholson, A.N., et al; "Antihistamines: Impaired Performance and the Tendency to Sleep; <i>Eur. J. Clin Pharmacol.</i> ; 30; pp. 27-32 (1986).

*Examiner	Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial this form with next communication to application.	

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

687-139

APPLICANT

SUNDERRAJ et al

FILING DATE

November 15, 2005

SERIAL NO.

10/556,900

TC/A.U.

1614

(Use several sheets if necessary)



	Nicholson, A.N., et al; "The H ₁ -Antagonist Mequitazine: Studies on Performance and Visual Function"; <i>Eur. J. Clin. Pharmacol.</i> ; 25; pp. 563-566 (1983).
	Akerstedt, T., et al; "Subjective and Objective Sleepiness in the Active Individual"; <i>Intern. J. Neuroscience</i> ; Vol. 52; pp. 29-37 (1990).
	Horne J.A., et al; "A Field Study of Sleep Disturbance: Effects of Aircraft Noise and Other Factors on 5,742 Nights of Actimetrically Monitored Sleep in a Large Subject Sample"; <i>Sleep</i> ; 17(2); pp. 146-159 (1994).
	Reyner, A., et al; "Gender- and Age-Related Differences in Sleep Determined by Home-Recorded Sleep Logs and Actimetry From 400 Adults"; <i>Sleep</i> ; 18(2); pp. 127-134 (1995).
	Corey, J.P., et al; "Nasal congestion: A review of its etiology, evaluation, and treatment"; <i>Ear, Nose & Throat Journal</i> ; 79(9); pp 690-702 (2000).
	Buyse, B.; "Postgraduaat Onderwijs in de Interne Geneeskunde"; <i>Tijdschr. Voor Geneeskunde</i> ; 58, No. 16; pp. 1055-1066 (2002).
	Findlay, J.W.A., et al; "Triprolidine Radioimmunoassay: Disposition in Animals and Humans"; <i>Journal of Pharmaceutical Sciences</i> ; Vol. 73, No. 10; pp. 1339-1344 (1984).
	DeAngelis, R.L., et al; "Determination of Triprolidine in Human Plasma by Quantitative TLC"; <i>Journal of Pharmaceutical Sciences</i> ; Vol. 66, No. 6; pp. 841-843 (1977).
	Williams, B.O., et al; "Bioavailability of pseudoephedrine and triprolidine from combination and single-ingredient products"; <i>Clinical Pharmacy</i> ; Vol. 3; pp. 638-643 (1984).
	Simons, K.J., et al; "An investigation of the H ₁ -receptor antagonist triprolidine: Pharmacokinetics and antihistaminic effects"; <i>J. Allergy Clin. Immunol.</i> ; Vol. 77, No. 2; pp. 326-330 (1986).
	Nicholson, A.N., "Effect of the Antihistamines, Brompheniramine Maleate and Triprolidine Hydrochloride, On Performance in Man"; <i>Br. J. Clin. Pharmac.</i> ; Vol. 8; pp; 321-324 (1979).
	Bye, C., et al; "Effects on the Human Central Nervous System of Two Isomers of Ephedrine and Triprolidine, and their Interaction"; <i>Br. J. Clin. Pharmac.</i> ; Vol. 1; pp. 71-78 (1974).
	Bye, C., et al; "Evidence for Tolerance to the Central Nervous Effects of the Histamine Antagonist, Triprolidine, in Man"; <i>Eur. J. Clin. Pharmacol.</i> ; Vol. 12; pp. 181-186 (1977).
	Kerr, J.S., et al; "The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers"; <i>Eur. J. Clin. Pharmacol.</i> ; Vol. 47; pp. 331-335 (1994).
	Rombaut, N., et al; "Effects of topical administration of levocabastine on psychomotor and cognitive function"; <i>Annals of Allergy</i> ; Vol. 67; pp. 75-79 (1991).
	Volkerts, E.R., et al; "Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performance and daytime sleepiness"; <i>Human Psychopharmacology</i> ; Vol. 7, pp. 227-238 (1992).
	Cohen, A.F., et al; "Pharmacodynamic and Pharmacokinetics of BW 825C: A New Antihistamine"; <i>Eur J. clin. Pharmacol</i> ; Vol. 28; pp. 197-204 (1985).
	Swire, F.M.M., et al; "Effects of a sedative and of a non-sedative H ₁ -antihistamine on the event-related potential (ERP) in normal volunteers"; <i>Psychopharmacology</i> ; Vol. 98; pp. 425-429 (1989).
	Clarke, C.H., et al; "Performance Studies with Antihistamines"; <i>Br. J. Clin. Pharmac.</i> ; Vol. 6; pp. 31-35 (1978).
	Betts, T., et al; "Effects of two antihistamine drugs on actual driving performance"; <i>British Medical Journal</i> ; Vol. 288; pp. 281-282 (1984).
	Stanley, N., et al; "Comparison of the effects of astemizole/pseudoephedrine and triprolidine/pseudoephedrine on CNS activity and psychomotor function"; <i>International Clinical Psychopharmacology</i> ; Vol. 11; pp. 31-36 (1996).
	Empey, D.W., et al; "A Double-Blind Crossover Trial of Pseudoephedrine and Triprolidine, Alone and in Combination, for the Treatment of Allergic Rhinitis"; <i>Annals Allergy</i> ; Vol. 34; pp. 41-46 (1975).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

687-139

APPLICANT

SUNDERRAJ et al

SERIAL NO.

10/556,900


(Use several sheets if necessary)

FILING DATE

November 15, 2005

TC/A.U.

1614



	Brookhuis, K.A., et al; "Acute and subchronic effects of the H ₁ -histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance"; <i>Br. J. Clin. Pharmac.</i> ; Vol. 36; pp. 67-70 (1993).
	Cohen, A.F., et al; "The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects"; <i>Clin Pharmacol Ther.</i> ; Vol. 38, No. 4; pp. 381-386 (1985).
	Nicholson, A.N., et al; "Performance Studies with the H ₁ -Histamine Receptor Antagonists, Astemizole and Terfenadine"; <i>Br. J. Clin. Pharmac.</i> ; Vol. 13; pp. 199-202 (1982).
	Hamilton, M., et al; "A Comparison of Triprolidine and Cyclizine on Histamine (H ₁) Antagonism, Subjective Effects and Performance Tests in Man"; <i>Br. J. Clin. Pharmac.</i> ; Vol. 13, pp. 441-444 (1982).
	Drouin, M.A., et al; "H ₁ Antihistamines: Perspective on the Use of the Conventional and New Agents"; <i>Annals of Allergy</i> ; Vol. 55; pp. 747-752 (1985).
	Paton, D.M., et al; "Clinical Pharmacokinetics of H ₁ -Receptor Antagonists (The Antihistamines); <i>Clin Pharmacokinetics</i> ; Vol. 10; pp. 477-497 (1985).
	Rombaut, N.E.I., et al; "Psychometric Aspects of Antihistamines: A Review"; <i>Human Psychopharmacology</i> ; Vol. 9; pp. 157-169 (1994).
	Karol, M.H., et al; "Methods to assess RAST results in patients exposed to chemical allergens"; <i>Allergy</i> ; Vol. 50; pp. 48-54 (1995).
	Gillberg, M., et al; "Relations Between Performance and Subjective Ratings of Sleepiness During a Night Awake"; <i>Sleep</i> ; Vol. 17, No. 3; pp. 236-241 (1994).

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.